AMRI announced Paul Feuerman has joined the company as senior vice president, general counsel and head of business development. Feuerman will be responsible for leading all AMRI's legal, M&A, and corporate affairs activities for the company's locations worldwide. Lori M. Henderson will transition from AMRI in the coming months to pursue new opportunities.
"Paul brings a breadth of knowledge to AMRI having served as general counsel to both public and privately held companies in the specialty pharmaceutical, generics, and clinical development sectors of the industry," said William S. Marth, president and chief executive officer, AMRI. "He has substantial M&A transaction expertise including experience with international transactions, business line extensions, public securities and debt offerings. This experience will be critical to us as we continue to look to grow our business. I would like to express my sincere gratitude to Lori for her significant and valuable contributions to AMRI during the past seven years. We wish her success with her future endeavors."
Previously, Feuerman was assistant general counsel, global business development at Mylan, where he provided counsel in support of several business transactions including, but not limited to, the $1.6 billion acquisition of Agila global injectables and oncolytics businesses; the $5.3 billion acquisition of Abbott's non-U.S. developed markets specialty and branded generics business; and HSR divestitures in support of the $7.2 billion acquisition of Meda. Prior to this, he served as General Counsel for SciDose LLC. Earlier in his career, he served as general counsel at Axonyx and executive vice president and general counsel at Schein Pharmaceutical Inc.
Feuerman holds a bachelor's degree from Trinity College, Hartford, Conn., and earned a Juris Doctor degree from Columbia Law School, New York, N.Y.